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This editorial refers to Differential effects of biological
DMARDs on peripheral immune cell phenotypes in pa-
tients with rheumatoid arthritis, Shingo Nakayamada
et al., on pages 164–74.
RA, like many chronic immune-mediated inflammatory
diseases, has benefited from the advent of biological dis-
ease-modifying therapies (biologics), which target specific
elements of the disease process. Used as part of a strategic
management approach, these treatments have significantly
improved outcomes for patients. However, restoration of
immune homeostasis and treatment-free remission are yet
to be achieved. Frustrated rheumatologists describe a
therapeutic ceiling to be breached only through an im-
proved understanding of RA pathophysiology [1].
The important contribution of immune cells to RA patho-
genesis is evident in the local and systemic manifestations
of disease and is confirmed by genome-wide association
studies, epigenetic screens and in vivo model systems.
Their role is further highlighted by the efficacy of drugs tar-
geting the molecules and cells of the immune system,
including TNFa and IL-6, the Janus kinase signalling path-
way, T-cell co-stimulation and antibody-producing B cells.
But which biologic is most appropriate for any individual
patient? And at what stage of disease is each drug most
efficacious? Current treatment regimens do not accom-
modate these questions, and instead, drugs are adminis-
tered in a conserved sequence until a favourable response
is achieved [2]. As it is now accepted that there are mul-
tiple disease endotypes encompassed within the diagno-
sis of RA and that there is a strategic window for treating
patients, after which favourable outcomes are reduced [3],
we have better reason than ever to search for new bio-
markers for stratification of patients to predict drug effi-
cacy, biomarkers for early diagnosis and drug targets for
patients unresponsive to existing therapies [1].
Although molecular techniques have proved useful in
predicting drug responses [4], immune cells have been
heralded as particularly promising biomarkers because
they both orchestrate the disease processes and are the
targets of existing therapies [5]. However, the relative
contributions, spatiotemporal arrangement and effector
profile of individual cell types across disease stages are
not well understood, a factor which limits our therapeutic
exploitation of molecular products including cytokines,
chemokines, receptors, adhesion molecules and kinases.
One of the sticking points in improving our understand-
ing of immune-mediated inflammatory disease pathogen-
esis is the standardization of assays to assess cell
phenotypes and show true pathological changes rather
than technical artefacts. The Human Immunology Project
Consortium (HIPC) is a grouping of six leading US re-
search institutes that have come together to address
this, producing methods for comparable immune profiling
across studies and research centres [6]. An article by
Shingo Nakayamada et al. [7] has applied these protocols
to the study of RA for the first time (published at
Rheumatology online ahead of print in March 2017).
In a large and complex experiment, the group used 25
antibodies and eight colour flow cytometry panels to pro-
file the differentiation status and effector phenotype of
major lymphocytic and myeloid cells in the peripheral
blood. The group analysed 108 RA patients and 33 age-
and sex-matched healthy control individuals. Among the
RA cohort, clinical and cellular measurements were made
at baseline and after 24weeks of treatment with a bio-
logic, targeting IL-6 (tocilizumab, n = 22), T-cell co-stimu-
lation (abatacept, n = 40) or TNFa (etanercept, infliximab,
adalimumab, golimumab or certolizumab pegol, n = 46)
[7]. A summary of findings is shown in Fig. 1.
Unsurprisingly, each drug gave rise to a distinct periph-
eral immune profile, reflective of the diversity of molecules
targeted. Indeed, many of the cellular responses observed
have been shown in smaller studies looking at individual
therapies or focused upon particular components of the
immune response. However, analysis of this large data set
together has provided a picture of the immune compart-
ments affected downstream of different drug targets, with
possible implications for combining biological therapies to
improve patient outcomes in the future.
Of course, there are shortcomings and limitations to the
scope of this study. For example, the fact that the patient
group was composed largely of individuals under treat-
ment with but unresponsive to MTX imposed limitations
upon comparisons with healthy controls. Furthermore, the
small number of healthy controls may have contributed to
the poor statistical power of the study and could have
been addressed. However, a number of important correl-
ations could be observed using abundant clinical data
within the RA group alone, showing relationships between
disease activity markers and the percentage of circulating
CD4+ memory T cells, Th17 cells, T-follicular helper (Tfh)
cells, CD8+ T cells, plasmablasts, IgM memory B cells,
classical and non-classical monocytes [7].
Importantly, the findings of this paper have contributed
to the hot topic areas of plasmacytoid dendritic cell (pDC)
biology, cells known for their role in type 1 interferon re-
sponses, [8] and Tfh cell [9] biology, cells that orchestrate
germinal centre formation and antibody responses. Here,
! The Author 2017. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com
RHEUMATOLOGY
Rheumatology 2018;57:1011
doi:10.1093/rheumatology/kex283
Advance Access publication 27 July 2017
E
D
IT
O
R
IA
L
D
ow
nloaded from
 https://academ
ic.oup.com
/rheum
atology/article-abstract/57/1/10/4049644 by U
niversity of Sunderland user on 03 Septem
ber 2019
Nakayamada et al. [7] show plasmacytoid dendritic cells
and Tfh cells to be significant independent predictors of
improvement in response to TNFa inhibitors and abata-
cept, respectively, adding these cells to the armamentar-
ium of peripheral blood biomarkers, which might allow
clinicians to select the most appropriate treatment for an
individual early in the disease process. However, capita-
lizing on this will rely upon the introduction of immune
profiling to clinical rheumatological practice, as is routine
in haematology for the management of lymphoprolifera-
tive disease.
Although low patient numbers meant that no predictor
of tocilizumab response was identified [7], the use of the
standardized HIPC protocol ensures that it is plausible to
add statistical power at a later date to interrogate anti-IL-6
responses further. Indeed, it is also tantalizing to imagine
comparing data from other interesting patients, such as
those receiving B-cell-depleting rituximab therapy or pa-
tients with other immune-mediated inflammatory diseases
receiving the same treatments.
In fact, it appears from the findings of this article that
successful treatment of RA hinges on control of B-cell
responses. The authors show profound effects on regula-
tory, effector and memory B-cell populations which, taken
together with the central role of Tfh cells in orchestrating
germinal centre formation and the role of plasmacytoid
dendritic cells in driving plasma cell responses, empha-
size that controlling the autoantibody response will be cru-
cial to improving outcomes in RA.
The immune profiling of peripheral blood as standardized
by HIPC and implemented by Nakayamada et al. [7] has
broad applications to identify biomarkers and improve
knowledge of pathophysiology in immune and inflammatory
diseases and across clinical disciplines. However, this tech-
nique can only hint at the spatiotemporal organization of
cells, because elevation in the blood may correspond to
proliferation, cell death or a depletion at other sites.
Consequently, there is a pressing need for complementary
studies and standardized procedures for analysis of
inflamed tissue and draining lymphoid organs to gain a full
understanding and exploit the role of immune cells in RA.
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FIG. 1 Summary of findings from [7]
Dark boxes depict cells which were independent, signifi-
cant predictors of a positive response to therapy. (>:
increased proportion; <: decreased proportion in periph-
eral blood).
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